Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes
Abstract
Metformin monotherapy appears to reduce mortality in patients with type 2 diabetes, with generally acceptable adverse effects. To determine whether any other glucose-lowering drugs have been shown to prevent or delay the onset of long-term clinical complications of diabetes, we conducted a systematic review of the literature using the standard Prescrire methodology. We identified only six randomised controlled trials, versus placebo or no treatment, that were designed to evaluate the efficacy of glucose-lowering drugs in preventing the clinical complications of type 2 diabetes. Three trials of various insulins failed to demonstrate a tangible benefit for patients with type 2 diabetes and moderate hyperglycaemia. In one trial, cardiovascular mortality appeared to be higher in the group treated with tolbutamide, a glucose-lowering sulphonylurea. In a trial lasting 11 years, another sulphonylurea, glibenclamide, appeared to reduce the incidence of diabetes complications, but it had no impact on mortality. The results of this trial are undermined by methodological flaws. In trials lasting up to 3 years, pioglitazone, alogliptin and saxagliptin had no effect in preventing the clinical complications of diabetes in patients with relatively high blood glucose levels. * In 2014, metformin is the only hypo- glycaemic drug that appears to reduce mortality among patients with type 2 diabetes in comparative trials. Compa- rative data suggesting that gliben- clamide prevents some…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.